165 results on '"Dutcher, Sarah K."'
Search Results
2. Validity of inpatient electronic health record‐based measures of oxygen‐related therapy in the United States: Lessons applicable for studying COVID‐19 endpoints.
3. Generic levothyroxine initiation and substitution among Medicare and Medicaid populations: a new user cohort study
4. Determinants of Generic Drug Substitution in the United States
5. Risk of Arterial and Venous Thrombotic Events Among Patients with COVID-19: A Multi-National Collaboration of Regulatory Agencies from Canada, Europe, and United States.
6. Six Years of the US Food and Drug Administration's Postmarket Active Risk Identification and Analysis System in the Sentinel Initiative: Implications for Real World Evidence Generation
7. Switching patterns of immediate‐release forms of generic mixed amphetamine salts products among privately and publicly insured individuals aged 15–64 years in the United States, 2013–2019
8. Risk of admission to hospital with arterial or venous thromboembolism among patients diagnosed in the ambulatory setting with covid-19 compared with influenza: retrospective cohort study
9. A Survey of Patients’ Perceptions of Pill Appearance and Responses to Changes in Appearance for Four Chronic Disease Medications
10. Evaluation of Switching Patterns in FDA’s Sentinel System: A New Tool to Assess Generic Drugs
11. COVID-19 vs Influenza for Risk of Thrombotic Events in Hospitalized Patients—Reply
12. Secular Trends in the Cost of Immunosuppressants after Solid Organ Transplantation in the United States
13. Treatment and care received by children hospitalized with COVID-19 in a large hospital network in the United States, February 2020 to September 2021.
14. Outcomes Associated with Generic Drugs Approved Using Product-Specific Determinations of Therapeutic Equivalence
15. Association of COVID-19 vs Influenza With Risk of Arterial and Venous Thrombotic Events Among Hospitalized Patients
16. Comparative effectiveness of generic and brand-name medication use: A database study of US health insurance claims
17. The Effect of Dementia on Medication Use and Adherence Among Medicare Beneficiaries With Chronic Heart Failure
18. Medication reconciliation during the transition to and from long-term care settings: A systematic review
19. Evaluating Confounding Control in Estimations of Influenza Antiviral Effectiveness in Electronic Health Plan Data
20. Validation of diagnosis codes to identify hospitalized COVID ‐19 patients in health care claims data
21. Correction to: Outcomes Associated with Generic Drugs Approved Using Product-Specific Determinations of Therapeutic Equivalence
22. Using inpatient electronic medical records to study influenza for pandemic preparedness
23. Who gets treated for influenza: A surveillance study from the US Food and Drug Administration’s Sentinel System
24. Validation of an electronic algorithm for Hodgkin and non‐Hodgkin lymphoma in ICD‐10‐CM
25. Effect of Medications on Physical Function and Cognition in Nursing Home Residents with Dementia
26. Who gets treated for influenza: A surveillance study from the US Food and Drug Administration’s Sentinel System
27. Using inpatient electronic medical records to study influenza for pandemic preparedness.
28. Comparative Effectiveness of Generic vs Brand-Name Levothyroxine in Achieving Normal Thyrotropin Levels
29. Pharmacotherapeutic Management of Dementia Across Settings of Care
30. Erratum. Use of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis. Diabetes Care 2020;43:90–97
31. Comparative Outcomes of Treatment Initiation With Brand vs. Generic Warfarin in Older Patients
32. Understanding utilization patterns of biologics and biosimilars in the United States to support postmarketing studies of safety and effectiveness
33. Using real‐world data to evaluate biosimilar switching
34. Use of Sodium–Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis
35. Supplemental Material, 820050_Appendix_1_and_Appendix_2 - Determinants of Generic Drug Substitution in the United States
36. Evaluation of Socioeconomic Status Indicators for Confounding Adjustment in Observational Studies of Medication Use
37. Generic and Brand-Name Thyroid Hormone Drug Use Among Commercially Insured and Medicare Beneficiaries, 2007 Through 2016
38. Determinants of Generic Drug Substitution in the United States
39. Determinants of Generic Drug Substitution in the United States
40. Understanding utilization patterns of biologics and biosimilars in the United States to support postmarketing studies of safety and effectiveness.
41. Use of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Type 1 Diabetes and Rates of Diabetic Ketoacidosis.
42. Differences in rates of switchbacks after switching from branded to authorized generic and branded to generic drug products: cohort study
43. Generic Versions of Narrow Therapeutic Index Drugs: A National Survey of Pharmacists' Substitution Beliefs and Practices
44. Provider and Patient Determinants of Generic Levothyroxine Prescribing: An Electronic Health Records–Based Study
45. Comparison of Generic-to-Brand Switchback Rates Between Generic and Authorized Generic Drugs
46. Switch-backs associated with generic drugs approved using product-specific determinations of therapeutic equivalence
47. Using real‐world data to evaluate biosimilar switching.
48. Generic Versions of Narrow Therapeutic Index Drugs: A National Survey of Pharmacists' Substitution Beliefs and Practices.
49. A Systematic Review of the Benefits and Risks of Anticoagulation Following Traumatic Brain Injury
50. PolyHEMA spheroids are an inadequate model for the drug resistance of the intractable solid tumors
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.